Methods for treating behavioral and other disorders using optica

Details Methods for treating behavioral and other disorders using optica Methods for treating behavioral and other disorders using optica

1998-01-23

1999-10-05

Weddington, Kevin E.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

A61K 31415

Patent

active

059624949

ABSTRACT:
Methods and compositions are disclosed utilizing the optically pure R(+) isomer of ondansetron. This compound is a potent drug for the treatment of nausea and vomiting associated with chemotherapy and radiation therapy, while avoiding the concomitant liability of adverse effects associated with the racemic mixture of ondansetron. The R(+) isomer of ondansetron is also useful for the treatment of behavioral disorders such as mood anxiety and schizophrenia, and such other conditions as may be related to R(+) ondansetron's activity as a competitive antagonist of serotonin receptor subtype 5-HT.sub.3 such as disorders of gastrointestinal motility, depression, migraine, and as an aid for alcohol withdrawal, nicotine withdrawal, and drug (benzodiazepine et al.) withdrawal, without the concomitant liability of adverse effects associated with the racemic mixture of ondansetron. Furthermore, the R(+) isomer of ondansetron is also useful for the treatment of cognitive disorders such as dementia or age-associated memory impairment, while avoiding the concomitant liability of adverse effects associated with the racemic mixture of ondansetron.

REFERENCES:
patent: 4695578 (1987-09-01), Coates et al.
patent: 4721720 (1988-01-01), Wootten et al.
patent: 4749718 (1988-06-01), Coates et al.
patent: 4753789 (1988-06-01), Tyers et al.
patent: 4783478 (1988-11-01), Wootten et al.
patent: 4835173 (1989-05-01), Tyers
patent: 4845115 (1989-07-01), Tyers
patent: 4847281 (1989-07-01), Tyers
patent: 4851407 (1989-07-01), Wootten et al.
patent: 4929632 (1990-05-01), Tyers et al.
patent: 4983621 (1991-01-01), Bunce et al.
patent: 5470868 (1995-11-01), Young
patent: 5712302 (1998-01-01), Young
Ariens, E.J., "Racemic therapeutics--ethical and regulatory aspects", Eur J Clin Pharmacol 41: 89-93 (1991).
Ariens, E.J., "Racemische therapeutica probleemmiddelen", Pharmaceutisch Weekblad 125(22): 552-554 (1990) (with English abstract).
Ariens, E.J., "Stereoselectivity in pharmacodynamics and pharmacokinetics", Schweiz. Med. Wschr. 120(5): 131-134 (1990).
Butler et al., "The pharmacological characterization of 5-HT.sub.3 receptors in three isolated preparations derived from guinea-pig tissues", Br. J. Pharmacol. 101: 591-598 (1990).
Hibert et al., "Conformation-Activity Relationship Study of 5-HT.sub.3 Receptor Antagonists and a Definition of a Model for This Receptor Site", J. Med. Chem. 33: 1594-1600 (1990).
Testa et al., "Racemates Versus Enantiomers in Drug Development: Dogmatism or Pragmatism?", Chirality 2: 129-133 (1990).
Jamali et al., J. Pharm Sci. 78(9): 695-715 (1989).
Butler et al., Br. J. Pharmacol., 94: 397-412 (1988).
Kris et al., J. Clin. Oncol., 6(4): 659-662 (1988).
Tyers et al., Eur. J. Cancer, 25: (Suppl. 1) S15-S19 (1989).
Grunberg et al., J. Clin. Oncol., 7(8): 1137-1141 (1989).
Schmoll, H.J., J. Clin Oncol., 25: (Suppl. 1) S35-S39 (1989).
Khojasteh et al., Cancer, 66(6): 1101-1105 (1990).
Marty M., Eur. J. Cancer Clin. Oncol., 25: (Suppl. 1) S41-S45 (1989).
DeMulder et al., Annals Intern. Med., 113:(11) 834-840 (1990).
Green et al., Cancer Chemother. Pharmacol., 24: 137-139 (1989).
Cubeddu et al., New Engl. J. Med., 322(12): 810-816 (1990).
Smyth J.F., Eur. J. Cancer Clin. Oncol., (Suppl. 1) S55-S57 (1989).
Graves T., DICP, Ann. Pharmacother, 24(11): (Suppl.) S51-S54 (1990).
Williston Park, Oncology, 4(9):98, 102(1990).
Priestman et al., Clin. Oncol., 2:71-75 (1990).
Costall et al., Pharmacol. Biochem. Behavior, 36(1):97-104(1990).
Merrifield et al., Clin. Pharm., 8(3): 187-199 (1989).
Van Liessum et al., Eur. J. Cancer, 26(6): 767-770 (1990).
Hosp. Formul., 25(3): 260 (1990).
Grunberg S.M., New Engl. J. Med., 322(12): 846-848 (1990).
Cunningham et al., Lancet, 1461-1463, Jun. 27, 1987.
Lancet, 1470-1471, Jun. 27, 1987.
Scrip No. 1626, 24-26, Jun. 29, 1991.

Affiliated with

Also associated with

Rating

Methods for treating behavioral and other disorders using optica does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for treating behavioral and other disorders using optica, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating behavioral and other disorders using optica will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1171969